That's the conclusion of a new study conducted in part at the University of North Carolina School of Medicine and published online by The Lancet this week.
The Phase II clinical trial, which investigates the efficacy of HP802-247 from Healthpoint® Biotherapeutics, was designed to determine effectiveness of certain cell concentrations and dosing frequencies of HP802-247, when combined with standard care in treatment of chronic venous leg ulcers.
William Marston, MD, professor of surgery in the UNC School of Medicine and medical director of the UNC Wound Healing Clinic, is an investigator in the study and one of the article authors.
Venous leg ulcers are caused by impaired circulation in the vein system of the legs from blockages or damage. Typically, venous leg ulcers become chronic wounds if, after three months of standard treatment, they fail to heal. Chronic venous leg ulcers appear as open lesions and need specialized medical care. An estimated 1-2 million Americans suffer from venous leg ulcers.
HP802-247 is a living human cell formula consisting of skin cells (keratinocytes and fibroblasts), which release growth factors into the wound on a cellular level for tissue regeneration, along with fibrinogen, which forms a "cellular web" for blood clotting and elasticity. During the study, 228 patients were enrolled at 28 medical centers in the United States, including UNC. Two different cell concentrations and two separate dosing frequencies were tested with standard care, in addition to a control group, over a 12-week period.
Dr. Marston says, "In the past, some chronic venous leg ulcers were treated with skin grafts, which occasionally could break down and also required the patient to heal a partial thickness wound at the skin graft harvest site. During this study, unique living cells were sprayed on the patient's wound, which interacted with the patient's cells for improved wound healing."
"In the study, we determined the best dosing of the fibroblast/keratinocyte preparation that markedly accelerated the rate of healing of the wounds. We are currently preparing a Phase III pivotal trial to start late this year," adds Dr. Marston.
The citation for the Phase II study manuscript is: Kirsner RS, Marston WA, Snyder RJ, Lee TD, Cargill DI, Slade HB. A Multicentre Randomised Dosing Trial of Spray-Applied Cell Therapy With Human Allogeneic Fibroblasts and Keratinocytes for the Treatment of Chronic Venous Leg Ulcers. Lancet 2012; pending.
The study was funded by Healthpoint® Biotherapeutics.
Tom Hughes | EurekAlert!
WAKE-UP provides new treatment option for stroke patients | International study led by UKE
17.05.2018 | Universitätsklinikum Hamburg-Eppendorf
First form of therapy for childhood dementia CLN2 developed
25.04.2018 | Universitätsklinikum Hamburg-Eppendorf
The more electronics steer, accelerate and brake cars, the more important it is to protect them against cyber-attacks. That is why 15 partners from industry and academia will work together over the next three years on new approaches to IT security in self-driving cars. The joint project goes by the name Security For Connected, Autonomous Cars (SecForCARs) and has funding of €7.2 million from the German Federal Ministry of Education and Research. Infineon is leading the project.
Vehicles already offer diverse communication interfaces and more and more automated functions, such as distance and lane-keeping assist systems. At the same...
A research team led by physicists at the Technical University of Munich (TUM) has developed molecular nanoswitches that can be toggled between two structurally different states using an applied voltage. They can serve as the basis for a pioneering class of devices that could replace silicon-based components with organic molecules.
The development of new electronic technologies drives the incessant reduction of functional component sizes. In the context of an international collaborative...
At the LASYS 2018, from June 5th to 7th, the Laser Zentrum Hannover e.V. (LZH) will be showcasing processes for the laser material processing of tomorrow in hall 4 at stand 4E75. With blown bomb shells the LZH will present first results of a research project on civil security.
At this year's LASYS, the LZH will exhibit light-based processes such as cutting, welding, ablation and structuring as well as additive manufacturing for...
There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?
At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...
So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics
Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...
25.05.2018 | Event News
02.05.2018 | Event News
13.04.2018 | Event News
25.05.2018 | Event News
25.05.2018 | Machine Engineering
25.05.2018 | Life Sciences